Brokers Offer Predictions for Atyr PHARMA FY2024 Earnings

Atyr PHARMA INC (NASDAQ:ATYRFree Report) – Cantor Fitzgerald issued their FY2024 earnings estimates for Atyr PHARMA in a research report issued on Thursday, January 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings of ($0.91) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Atyr PHARMA’s current full-year earnings is ($0.89) per share.

Atyr PHARMA (NASDAQ:ATYRGet Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01).

Other research analysts also recently issued reports about the company. Wells Fargo & Company started coverage on Atyr PHARMA in a research note on Friday, October 4th. They issued an “overweight” rating and a $17.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $35.00 price objective on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Atyr PHARMA has an average rating of “Buy” and a consensus target price of $19.25.

Read Our Latest Stock Analysis on Atyr PHARMA

Atyr PHARMA Price Performance

Shares of NASDAQ:ATYR opened at $3.29 on Monday. The firm has a market capitalization of $276.17 million, a PE ratio of -3.50 and a beta of 1.08. The business has a 50-day moving average of $3.37. Atyr PHARMA has a fifty-two week low of $1.39 and a fifty-two week high of $4.22. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.

Institutional Trading of Atyr PHARMA

A hedge fund recently raised its stake in Atyr PHARMA stock. JPMorgan Chase & Co. raised its position in Atyr PHARMA INC (NASDAQ:ATYRFree Report) by 52.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,440 shares of the company’s stock after acquiring an additional 10,754 shares during the period. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 as of its most recent SEC filing. 61.72% of the stock is owned by institutional investors and hedge funds.

Atyr PHARMA Company Profile

(Get Free Report)

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Featured Articles

Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.